|Dr. Rodney W. Lappe Ph.D.||Exec. Chairman||N/A||N/A||1955|
|Dr. Charles M. Baum M.D., Ph.D.||Chief Exec. Officer, Pres and Director||712.91k||N/A||1958|
|Dr. James Christensen Ph.D.||Chief Scientific Officer and Sr. VP||436.93k||N/A||1968|
|Dr. Isan Chen M.D.||Chief Medical & Devel. Officer and Exec. VP||509k||N/A||1962|
|Mr. Jamie A. Donadio Ph.D.||Chief Financial Officer and Sr. VP||N/A||N/A||1975|
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; and Array BioPharma, Inc. to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Mirati Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.